Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
VSTM Verastem, Inc. daily Stock Chart
VSTM [NASD]
Verastem, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.00 Insider Own7.08% Shs Outstand150.75M Perf Week34.76%
Market Cap379.89M Forward P/E- EPS next Y-0.44 Insider Trans0.00% Shs Float137.91M Perf Month31.94%
Income-149.20M PEG- EPS next Q-0.22 Inst Own10.60% Short Float8.56% Perf Quarter81.29%
Sales17.50M P/S21.71 EPS this Y-79.40% Inst Trans-28.51% Short Ratio4.33 Perf Half Y96.88%
Book/sh0.09 P/B28.00 EPS next Y41.30% ROA-74.60% Target Price4.08 Perf Year-13.99%
Cash/sh0.50 P/C5.03 EPS next 5Y1.74% ROE-358.60% 52W Range0.83 - 3.49 Perf YTD88.06%
Dividend- P/FCF- EPS past 5Y0.70% ROI-119.40% 52W High-27.79% Beta1.96
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin92.90% 52W Low203.61% ATR0.35
Employees135 Current Ratio2.80 Sales Q/Q200.00% Oper. Margin- RSI (14)55.94 Volatility13.81% 18.13%
OptionableYes Debt/Eq14.39 EPS Q/Q-230.10% Profit Margin- Rel Volume1.82 Prev Close2.56
ShortableYes LT Debt/Eq14.39 EarningsMar 17 AMC Payout- Avg Volume2.73M Price2.52
Recom2.20 SMA204.69% SMA5017.09% SMA20064.65% Volume4,972,141 Change-1.56%
Jun-20-19Downgrade BTIG Research Buy → Neutral
May-10-19Downgrade Raymond James Outperform → Mkt Perform
Jul-13-18Initiated BTIG Research Buy $17
May-02-18Initiated Seaport Global Securities Buy $14
Mar-08-18Initiated B. Riley FBR, Inc. Buy $15
Sep-07-17Reiterated H.C. Wainwright Buy $6.50 → $10
Apr-13-17Initiated Oppenheimer Outperform
Mar-24-17Reiterated H.C. Wainwright Buy $5 → $6.50
Sep-29-15Downgrade Raymond James Strong Buy → Outperform
Sep-29-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15Downgrade Jefferies Buy → Hold
Sep-29-15Downgrade Cantor Fitzgerald Buy → Hold
Sep-28-15Downgrade ROTH Capital Buy → Neutral $23 → $2
Sep-28-15Downgrade Mizuho Buy → Neutral $21 → $2
Sep-09-15Initiated Raymond James Strong Buy
May-12-15Reiterated UBS Buy $30 → $24
Apr-08-15Initiated H.C. Wainwright Buy $16
Jan-23-15Reiterated ROTH Capital Buy $29 → $23
Jul-08-14Resumed Oppenheimer Perform
Feb-11-14Initiated Mizuho Buy $21
Mar-19-20 11:30AM  Has Verastem (VSTM) Outpaced Other Medical Stocks This Year? Zacks +12.05%
Mar-18-20 07:01AM  Verastem Sees Hammer Chart Pattern: Time to Buy? Zacks -15.31%
Mar-11-20 04:05PM  Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial Results Business Wire -18.12%
Mar-10-20 09:28AM  Verastem, Inc. (VSTM) Shares March Higher, Can It Continue? Zacks
Feb-28-20 06:05AM  Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development Programs Business Wire +46.07%
06:00AM  Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors Business Wire
Feb-05-20 11:52AM  Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-29-20 07:06AM  Verastem Oncology Announces Dosing of First Patient in CSPCs Chinese Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma Business Wire
Jan-21-20 11:14AM  Those Who Purchased Verastem (NASDAQ:VSTM) Shares Five Years Ago Have A 74% Loss To Show For It Simply Wall St. -5.79%
Jan-09-20 09:00AM  Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up Zacks
Jan-08-20 08:12AM  The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results Benzinga +36.51%
07:00AM  Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 Business Wire
Jan-06-20 07:00AM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-17-19 07:03PM  Do Hedge Funds Love Verastem Inc (VSTM)? Insider Monkey -5.93%
Dec-11-19 08:46AM  Implied Volatility Surging for Verastem (VSTM) Stock Options Zacks
Dec-07-19 09:00AM  Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting Business Wire
Nov-25-19 08:57AM  Implied Volatility Surging for Verastem (VSTM) Stock Options Zacks
07:00AM  Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib) Business Wire
Nov-15-19 11:16PM  Edited Transcript of VSTM earnings conference call or presentation 29-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Nov-13-19 07:00AM  Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award Business Wire
Nov-12-19 08:12AM  Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048 Business Wire
Nov-06-19 09:15AM  Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting Business Wire
Oct-30-19 07:01AM  The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings Benzinga -13.60%
Oct-29-19 07:35PM  Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates Zacks -6.02%
04:17PM  Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress Business Wire
Oct-23-19 07:00AM  Verastem Oncology Announces COPIKTRA (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International Congress Business Wire +19.47%
Oct-17-19 07:00AM  Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019 Business Wire
Oct-09-19 11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
Oct-08-19 10:02AM  Verastem's (VSTM) Copiktra Gets Orphan Drug Designation Zacks
Oct-07-19 07:00AM  Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Business Wire
Oct-04-19 01:41PM  How Many Verastem, Inc. (NASDAQ:VSTM) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
07:00AM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-03-19 02:25PM  Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma Business Wire +8.93%
07:00AM  Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Malignancies Business Wire
Sep-26-19 07:00AM  Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference Business Wire
Sep-20-19 01:00PM  Verastem Oncology Announces COPIKTRA (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia Business Wire
Sep-03-19 04:05PM  Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference Business Wire
Aug-06-19 08:52PM  Edited Transcript of VSTM earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 01:13PM  Verastem Inc (VSTM) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 07:25PM  Verastem (VSTM) Reports Q2 Loss, Tops Revenue Estimates Zacks +6.00%
04:05PM  Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress Business Wire
Jul-30-19 07:00AM  The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings Benzinga
Jul-29-19 04:05PM  Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer Business Wire
Jul-26-19 07:26AM  The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint Benzinga +12.21%
Jul-25-19 04:05PM  Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development and Commercialization of COPIKTRA® (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa Business Wire
07:00AM  Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019 Business Wire
Jul-23-19 01:04PM  What Kind Of Shareholders Own Verastem, Inc. (NASDAQ:VSTM)? Simply Wall St.
Jul-03-19 07:00AM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-25-19 08:53PM  Hedge Funds Have Never Been This Bullish On Verastem Inc (VSTM) Insider Monkey
Jun-24-19 08:33AM  Verastem Up on Positive Data From Early-Stage Copiktra Study Zacks
Jun-21-19 09:01AM  Verastem Shares Response Rate From COPIKTRA Data Benzinga +13.84%
07:00AM  Verastem Oncology Presents COPIKTRA (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma Business Wire
Jun-20-19 09:41AM  The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure Zacks -16.32%
07:00AM  Verastem Oncology Announces Leadership Changes Business Wire
Jun-19-19 11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
Jun-17-19 07:00AM  Verastem Oncology Presents COPIKTRA (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting Business Wire +25.00%
May-30-19 07:00AM  Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference Business Wire
May-24-19 02:42PM  Did You Manage To Avoid Verastem's (NASDAQ:VSTM) Devastating 85% Share Price Drop? Simply Wall St.
02:35PM  Edited Transcript of VSTM earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-16-19 07:00AM  Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference Business Wire
May-15-19 05:16PM  Verastem Oncology to Present New COPIKTRA (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study Business Wire
May-13-19 06:44AM  Verastem Inc (VSTM) Q1 2019 Earnings Call Transcript Motley Fool -5.15%
May-09-19 06:45PM  Verastem (VSTM) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.03%
05:34PM  Verastem: 1Q Earnings Snapshot Associated Press
04:05PM  Verastem Oncology Reports First Quarter 2019 Financial Results Business Wire
May-02-19 07:00AM  Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019 Business Wire
Apr-23-19 04:05PM  Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility Business Wire +6.07%
Apr-04-19 04:05PM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-02-19 07:00AM  Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Mar-18-19 04:08PM  Edited Transcript of VSTM earnings conference call or presentation 12-Mar-19 8:30pm GMT Thomson Reuters StreetEvents +8.68%
Mar-14-19 03:00PM  3 Penny Stocks That Could Make You Rich -- or Regretful Motley Fool -5.37%
Mar-13-19 01:59PM  Why Verastem Stock Broke Down Today Motley Fool
10:42AM  Verastem (VSTM) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:27AM  The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie Benzinga
Mar-12-19 06:30PM  Verastem (VSTM) Reports Q4 Loss, Misses Revenue Estimates Zacks +9.09%
05:33PM  Verastem: 4Q Earnings Snapshot Associated Press
04:08PM  Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments Business Wire
07:00AM  Verastem Oncology to Present at Upcoming Investor Conferences Business Wire
Mar-11-19 08:46AM  Do Options Traders Know Something About Verastem (VSTM) Stock We Don't? Zacks +6.45%
Mar-07-19 05:01PM  Verastem Oncology Presents Further COPIKTRA (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Malignancies Business Wire
02:33PM  Why Verastem, Inc. (NASDAQ:VSTM) Could Have A Place In Your Portfolio Simply Wall St.
Mar-04-19 07:00AM  Verastem Oncology Presents Phase 3 DUO Data Evaluating COPIKTRA (Duvelisib) in Patients with CLL/SLL Who Have Progressed Following Two Prior Lines of Therapy Business Wire
Mar-01-19 04:49PM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-26-19 07:00AM  Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019 Business Wire
Feb-22-19 08:15AM  Investor Expectations to Drive Momentum within Verastem, Molson Coors Brewing, SL Green Realty, UnitedHealth Group, TechTarget, and Icahn Enterprises Discovering Underlying Factors of Influence GlobeNewswire
Feb-21-19 07:00AM  Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-20-19 08:43AM  CORRECTING and REPLACING Verastem Oncology Announces Key Management Appointments Business Wire -5.15%
Feb-14-19 07:00AM  Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology Business Wire
Feb-04-19 04:05PM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-30-19 08:30AM  2 Small-Cap Biotech Stocks That Are on My Radar TheStreet.com +5.23%
Jan-11-19 07:48PM  Here's Why Verastem Tumbled 34.1% in December Motley Fool -8.15%
Jan-09-19 11:58AM  4 Healthcare Stocks Looking To Set January Highs ACCESSWIRE
Jan-07-19 04:05PM  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.57%
Jan-04-19 07:59AM  The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO Benzinga +7.41%
07:30AM  New Research: Key Drivers of Growth for The Blackstone Group, Barnes & Noble, Verastem, Littelfuse, Essendant, and Anworth Mortgage Asset Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-03-19 04:05PM  Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress Business Wire
07:01AM  Verastem Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-23-18 05:26AM  Hedge Funds Are Crazy About Verastem Inc (VSTM) Insider Monkey
Dec-20-18 10:47AM  Have Insiders Been Buying Verastem, Inc. (NASDAQ:VSTM) Shares This Year? Simply Wall St.
07:00AM  Verastem Oncology Added to the NASDAQ Biotechnology Index® Business Wire
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.
open in yahoo | open in reuters | open in google